Neovascular Age‐Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect

Mulyukov, Zufar; Weber, Sebastian; Pigeolet, Etienne; Clemens, Andreas; Lehr, Thorsten; Racine, Amy

doi:10.1002/psp4.12322

Cited by 11 publications

(28 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The general model structure was first developed by Holz et al 21 based on data of the RCTs MARINA, ANCHOR, and PIER. It was then extended and applied by Mulyukov et al 22 and Agostini et al 23 . In the present study, the model is extended and applied for the first time to real-world data.…”

Section: Methodsmentioning

confidence: 99%

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD

Ziemssen

Agostini

Feltgen³

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that often leads to severe and permanent vision loss. Early initiation of anti-vascular endothelial growth factor (anti-VEGF) therapy has been shown to preserve vision in nAMD patients. Concurrently, treatment outcomes in real-world are inferior to those reported in clinical trials. The most likely reasons observed are fewer treatment-intensity in routine clinical practice than in clinical trials. The other possibility could be the delay in starting treatment and the re-treatment interval. Although a negative impact of aforementioned parameters seems obvious, quantitative impact measures remain elusive in a real-world setting due to a lack of an ‘optimal treatment’ control group. To overcome this shortcoming, we developed, validated, and applied a model to assess and quantify the impact of anti-VEGF administration variables on visual acuity development in a prospective nAMD patient cohort. The model was further applied to probe the impact of the COVID-19 pandemic on visual progressions in nAMD patients. The presented model paves the way to systematically explore and evaluate realistic interventions in the current treatment paradigm, that can be adopted in routine clinical care.

show abstract

Section: Methodsmentioning

confidence: 99%

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD

Ziemssen

Agostini

Feltgen³

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…We first present a continuous model for the response of the measurements to the treatment regimen. Our general approach is motivated by the work in [5], though the terms we use are different.…”

Section: Section 2: Linear Continuous Modelsmentioning

confidence: 99%

Parametric Models for Clinical Measurements in Ophthalmology

Edwards

Barnes

Dhar

et al. 2022

Preprint

View full text Add to dashboard Cite

The standard of care treatment for neovascular age-related macular degeneration, delivered as ocular injection, is based on anti-vascular endothelial growth factor (anti-VEGF). The course of treatment may need to be modified quickly for certain patients based on their response. Models that track both the concentration and the response to an anti-VEGF treatment are presented. The specific focus is to assess the existence of analytical solutions for the different types of models. Both an ODE-based model and a map-based model illustrate the dependence of the solution on various biological parameters and allow the measurement of patient-specific parameters from experimental data. A PDE-based model incorporates diffusive effects. The results are consistent with observed values, and could provide a framework for practitioners to understand the effect of the therapy on the progression of the disease in both responsive and non-responsive patients.

show abstract

“…Macular disintegration is an ailment that affects macular part of the retina and the main reason for vision loss in AMD [56]. 2014 the widespread presence of AMD was about 8.7%.…”

Section: Age Related Macular Degenerationmentioning

confidence: 99%

Restoring Vision by Regenerative Medicine Using Stem Cell: A Review

Rk¹,

Ibrahim²,

Shafiq³

et al. 2018

J Biomol Res Ther

View full text Add to dashboard Cite

Restoring vision is the most important center of attention of our research program, On the other hand, to attain our objective and convey the preeminent eminence of stem cell therapy; we have to understand the fundamental biology of stem cells. (RPE) Retinal Pigmented epithelium layer degenerates and contributing to a succession of actions resulting in visual impairments. Regenerative medicine holds promise for the spanning almost for all body system and the eye is an ideal organ to use in research because it is the only part of nervous system that is the visible and easily accessible. This review outlines advances in therapy and the main spotlight for the improvement and advance of cell therapies that are being confronted today.

show abstract

Neovascular Age‐Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect

Cited by 11 publications

References 31 publications

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD

Parametric Models for Clinical Measurements in Ophthalmology

Restoring Vision by Regenerative Medicine Using Stem Cell: A Review

Contact Info

Product

Resources

About